Clinical trial Recruiting at 1 site Interventional Ages 18 to 70

Repeated verbal orientation reminders to reduce emergence agitation after general anesthesia

Official title: Effect of a Repeated Verbal Reminder of Orientation on Emergence Agitation After General Anesthesia

Run by Shaukat Khanum Memorial Cancer Hospital & Research Centre · NCT07510516 · Data updated 2026-11-12

We'll try prerecorded verbal orientation reminders through headphones to see if they reduce wake-up agitation in adults (18–70) having elective laparoscopic abdominal surgery with sevoflurane general anesthesia.

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment62 (estimated)
SponsorShaukat Khanum Memorial Cancer Hospital & Research Centre
Academic / other
Locations1 site (Lahore, Punjab Province)
StatusRecruiting
StartedJanuary 29, 2025
Main results expectedJuly 31, 2026
Study endsOctober 30, 2026
Registry record updatedApril 3, 2026
Trial IDNCT07510516 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–70 scheduled for elective laparoscopic abdominal surgery under sevoflurane general anesthesia without hearing loss, documented cognitive or neurological deficits, BMI >35, ASA IV status, or current antipsychotic use are ideal candidates.

Probably not a fit

Patients planned for TIVA or inhalational agents other than sevoflurane, ambulatory surgery, those with hearing impairment, documented cognitive or neurologic deficits, very high BMI, ASA 4, or on antipsychotics are unlikely to be eligible or to receive benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial will enroll 42 adults aged 18–70 scheduled for elective laparoscopic abdominal surgery at Shaukat Khanum Memorial Hospital, Lahore. Participants will be randomized 1:1 to an orientation group receiving repeated prerecorded voice reminders via headphones or to a control group who only hear their own name. Emergence agitation will be measured in the operating room using the Riker Sedation-Agitation Scale, with incidence of emergence agitation as the primary outcome. Secondary outcomes include time from sevoflurane discontinuation to eye opening, extubation, discharge to PACU, pain scores, and length of PACU stay.

Why it matters

Potential benefit: If successful, the intervention could lower rates of emergence agitation and speed early postoperative recovery, potentially shortening PACU stays and reducing patient distress.

How similar studies have gone: Some prior small studies and perioperative protocols suggest verbal reorientation or environmental cues can reduce agitation or delirium, but the evidence is limited and mixed.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Adult patients

* Aged 18 to 70 years
* Scheduled to undergo elective laparoscopic abdominal surgery will be screened for eligibility.

Exclusion Criteria:

* Include TIVA and inhalational agent other than sevoflurane, American Society of Anesthesiologists (ASA) physical status 4,
* BMI \>35 kg/m\^2,
* Pre-existing conditions associated with neurological deficit,
* Cognitive impairment if documented by neurologist
* Hearing disorders
* Use of antipsychotic medications,
* Plan for ambulatory surgery and participant refusal.

Where it's running

  • Skmch & Rc
    Lahore, Punjab Province, Pakistan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.